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ABSTRACT 
This case report describes the induction of extrapyramidal symptoms with fluoxetine, which 
is reported to be a rare phenomenon. A dopamine blockade at the nigrostriatal level primarily 
mediated by serotonin has been proposed as the probable mechanism. 
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In recent years there have been several 
case reports of extrapyramidal symptoms as a 
result of treatment with fluoxetine (Tate, 1989; 
Lipinski et al., 1989; Fallon & Liebowitz, 1991; 
Steur, 1993; Arya, 1994; Coutler & Pillans, 
1995). The symptoms noted include 
bradykinesia, cogwheel rigidity and akathisia. 
Extrapyramidal symptoms develop in patients 
while being treated with fluoxetine or the 
baseline extrapyramidal symptoms are reported 
to have worsened. As fluoxetine is a commonly 
used and well-tolerated antidepressant, looking 
into this rare and intriguing side effect is 
worthwhile. Clinically, one runs the risk of los-
ing the patients due to suicide because of this 
distressing side-effect or noncompliance. We 
report two cases of fluoxetine-induced extrapy-
ramidal symptoms and possible mechanisms 
responsible for the induction of these side-ef-
fects are discussed. 
CASE1 
Mr. A, a 25 year-old male reported to our 
hospital with a major depressive episode for two 
weeks. He had a manic episode one year be-
fore and was treated successfully elsewhere. 
In the outpatient department he was started on 
fluoxetine 20 mg daily. Five days later he re-
ported with severe restlessness and inability to 
sit at ease in one place for any length of time. 
He had severe disturbance in sleep and marked 
reduction in appetite. Subjectively he was ex-, 
pressing tearfulness without any reason. De-
tailed physical examination revealed significant 
cogwheel rigidity, bradykinesia, reduce eye 
blinking and mask like face with akathisia. He 
had not received any other medication for this 
episode but for fluoxetine. As the emergence 
of such side-effects may be linked to fluoxetine 
it was immediately stopped and lithium 900 mg 
per day with amoxapine 50 mg daily was started. 
After three days he was much better with sig-
nificant reduction in depression and had no ex-
trapyramidal symptoms including akathisia. The 
same medication was continued further and he 
remained well. 
CASE 2 
Mr. AH was a 19 year-old male, admit-
ted in our hospital with one year history of de-
pressive syndrome. He also had significant 
trichotillomania with trichophagia for the same 
period. He was started on fluoxetine increased 
up to a maximum dosage of 60 mg per day. 
Due to inadequate response fluoxetine was 
potentiated with lithium. Following this he 
started showing the features of hypomania, so 
fluoxetine was reduced to 20 mg per day and 
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haloperidol 10 mg per day was started. With 
this regime he developed severe side effects 
for which trihexyphenidyl 4 mg per day was 
added. A gradual improvement was noticed 
and during discharge there was remarkable im-
provement in hypomanic and compulsive 
symptoms. Next few months he came regularly 
for follow up and was maintaining well. There 
after he stopped visiting the hospital. 
After nine months he was readmitted with 
florid manic symptoms and significant compul-
sive symptoms like trichotillomania and 
trichophagia for which haloperidol 10 mg per 
day and fluoxetine 20 mg per day was started. 
Within six days he developed akathisia and 
pseudoparkinsonism. Haloperidol was 
immediately stopped and trihexyphenidyl 4 mg 
per day was added and continued for one week. 
Within few days he became completely free 
from extrapyramidal symptoms. Because of the 
distressing compulsive symptoms, fluoxetine 
was increased to 40 mg per day. Two weeks 
after this he had recurrence of extrapyramidal 
symptoms with severe bradykinesia, cogwheel 
rigidity, tremor and facial flattening. After stop-
ping the fluoxetine, within one week, he com-
pletely recovered from extrapyramidal symp-
toms. Subsequently, due to repeated mania-like 
episodes and poor drug compliance he was 
started on depot injection flupenthixol (40 mg 
i.m. every three weeks). With this regimen he 
is maintaining well and is coming for follow up 
regularly. 
DISCUSSION 
The mechanism by which fluoxetine, a 
primary serotonergic inhibitor induces or 
worsens the extrapyramidal side effect is still 
speculative. Opler(1991) proposed a three-neu-
ronal model of extrapyramidal motor system by 
which dopaminergic, cholinergic and gabaergic 
agents can have effects on the extrapyramidal 
system. In this model the major input into the 
basal ganglia is the inhibitory dopamine nigros-
triatal tract, second neuron is the excitatory 
cholinergic interneurone and third neuron 
represents major inhibitory gabaergic flow. The 
blockade ofdopamine tract causes disinhibrtion 
of the second neuron and subsequently 
increased firing of gabaergic neurons that 
inibit the voluntary motor system observed clini-
cally as bradykinesia. However, this mode! does 
not explain the role of serotonergic agents in 
the extrapyramidal system. Hamilton & Opier 
(1992) postulated a "four neuronal model" in 
which they added a first neuron that is 
serotonergic arising from raphe nucleus 
causing inhibition in the firing of nigrostriatal 
tracts and, therefore, capable of producing ex-
trapyramidal effects. There has been evidence 
for the presence of serotonergic projection from 
the raphe nucleus to substantia nigra (Azmita, 
1978). The extrapyramidal system has rich 
innervation of serotonergic fibres. Pharmaco-
logical evidence showed that serotonergic 
antagonists like cyproheptadine and 
methysergide could relieve the catalepsy 
induced by neuroleptics in rodents (Carter & 
Pycock, 1977). Fluoxetine has also been 
reported to inhibit the catecholamine synthesis 
in dopamine rich areas of forebrain, hippocam-
pus and striatum (Baldessarini & Marsh, 1990). 
This serotonin-induced inhibition of dopamine 
neurons may result in decreased stimulation of 
dopamine with consequent extrapyramidal 
symptoms. 
The cases in this report show the 
occurrence of severe pseudo parkinsonian 
symptoms and akathisia with fluoxetine. 
Neither of them reported suicidal ideation that 
is contrary to the previous reports (Teicher et 
al., 1990; Rothschild & Locke, 1991; Tueth, 
1994). A possible reason could be the 
detection of side effects early in treatment, and 
immediate intervention hindered the evolution 
of suicidal ideation as a response to the feeling 
of akathisia. From reports in literature and the 
cases in this report, it appears that fluoxetine 
may be associated with extrapyramidal 
reactions. Furthermore, because of its potent 
inhibitory- effect on hepatic oxidative 
metabolism, the potential for increased levels 
88 FLUOXETINE INDUCED EXTRAPYRAMIDAL SYMPTOMS : CASE REPORTS 
of concomitant psychotropic medicines and 
increased side effects that may include extrapy-
ramidal symptoms, should be borne in mind. 
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